Mas-Related G Protein–Coupled Receptor-X2 and Its Role in Non-immunoglobulin E–Mediated Drug Hypersensitivity - 23/04/22
, Hydar Ali, PhD b, ⁎ Résumé |
A diverse group of Food and Drug Administration–approved cationic drugs including antibiotics, neuromuscular blocking drugs, opioids, antidepressants, and radiocontrast media activate mast cells and cause hypersensitivity reactions by both an immunoglobulin E IgE-dependent and independent manner. The recent discovery that these drugs activate mast cells via the G protein–coupled receptor known as Mas-related GPCR-X2 (MRGPRX2) has represented a paradigm shift of how drug hypersensitivity reactions are viewed. This article provides an overview of the current status of the role of MRGPRX2 on non-IgE-mediated drug hypersensitivity. Potential risk factors and evaluation for suspected MRGPRX2-mediated drug reactions are also discussed.
Le texte complet de cet article est disponible en PDF.Keywords : MRGPRX2, Mast cells, Drug hypersensitivity, Anaphylaxis
Plan
Vol 42 - N° 2
P. 269-284 - mai 2022 Retour au numéro
Article précédent
- Anaphylaxis to Excipients in Current Clinical Practice : Evaluation and Management
- Maria A. Bruusgaard-Mouritsen, Shuaib Nasser, Lene H. Garvey, Matthew S. Krantz, Cosby A. Stone
- Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models
- Benjamin C. Park, Cosby A. Stone, Anna K. Dewan, Douglas B. Johnson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?